Long COVID-19LCCSNCT07005947
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
An observational study of Long COVID-19 and Acute COVID-19, run by CND Life Sciences at 1 site in United States.
Trial summary
This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Long COVID-19, Acute COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS)
- How many people
- 237 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Nov 2023to 30 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Male and females ages 18-80 who have been diagnosed with one of the following: 1. Long COVID defined by NIH PASC criteria OR 2. Acute COVID who tested positive for COVID without persistent symptoms OR 3. Postural orthostatic tachycardia syndrome (POTS) OR 4. Diabetic neuropathy
Who may be able to join
- Long COVID-19 defined by NIH PASC criteria OR
- Acute COVID-19 who tested positive for COVID-19 without persistent symptoms OR
- Postural orthostatic tachycardia syndrome (POTS) OR
- Diabetic neuropathy
Who cannot join
- Clinical evidence of severe peripheral vascular disease
- History of ulceration, poor wound healing or vascular claudication
- History of allergic reaction to local anesthesia (for biopsy collection)
- Use of oral anticoagulants (aspirin or Plavix alone is allowed)
- History of a bleeding disorder
Trial locations and contacts
1 site in 1 country.
About this study
This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.
Read the detailed description
This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system. The evaluations will include clinical assessments, neurologic exams, patient reported outcome surveys, and skin biopsies from three locations. Data will be collected on the amount of P-SYN in cutaneous nerve fibers. The cohorts of interest are as follows:
- 100 participants with Long COVID-19 defined by NIH PASC criteria
- 100 participants with acute COVID-19 who tested positive for COVID-19 without persistent symptoms defined WHO criteria
- 50 participants with postural orthostatic tachycardia syndrome (POTS)
- 50 participants with diabetic neuropathy
There are no plans for additional visits at this time.
If interested to learn more about this study, please complete the form here for someone to contact you. "here" would take you to the said form.
- Conditions
- Long COVID-19, Acute COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS), Diabetic Neuropathy
- Keywords
- COVID, Diabetic Neuropathy, Postural orthostatic tachycardia syndrome, POTS
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Postural Orthostatic Tachycardia Syndrome, Diabetic Neuropathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Long COVID | Participants with Long COVID | |
| Acute COVID | Participants with acute COVID who tested positive for COVID without persistent symptoms | |
| Postural Orthostatic Tachycardia Syndrome (POTS) | Participants with postural orthostatic tachycardia syndrome (POTS) | |
| Diabetic neuropathy | Participants with diabetic neuropathy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathology and nervous system changes that occur in patients suffering from sensory and autonomic function changes
This is a single site study of subjects with Long COVID, subject with a previous positive COVID test without persistent symptoms, and POTS subjects and diabetics. Neurocutaneous biosignatures will provide insight into the pathology and nervous system changes that occur in patients suffering from sensory and autonomic function changes.
Measured: Current - December 31,2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2025
- Study start30 Nov 2023
- Primary completion31 Dec 2025
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 237 participants (actual)
Sponsor and investigators
- Lead sponsor
- CND Life Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07005947
- Sponsor's protocol ID
- The LCCS Study
- Acronym
- LCCS
- Status last verified
- Jul 2026
- First submitted
- 3 Jun 2025
- Last updated
- 2 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
- ClinicalTrials.gov ID
- NCT07005947
- Acronym / sponsor ID
- LCCS / The LCCS Study
- Conditions
- Long COVID-19, Acute COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS), Diabetic Neuropathy
- Keywords
- COVID, Diabetic Neuropathy, Postural orthostatic tachycardia syndrome, POTS
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 237 participants (actual)
- Lead sponsor
- CND Life SciencesUniversity, hospital or other
- Study start
- 30 Nov 2023 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 5 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.
Detailed description
This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system. The evaluations will include clinical assessments, neurologic exams, patient reported outcome surveys, and skin biopsies from three locations. Data will be collected on the amount of P-SYN in cutaneous nerve fibers. The cohorts of interest are as follows:
- 100 participants with Long COVID-19 defined by NIH PASC criteria
- 100 participants with acute COVID-19 who tested positive for COVID-19 without persistent symptoms defined WHO criteria
- 50 participants with postural orthostatic tachycardia syndrome (POTS)
- 50 participants with diabetic neuropathy
There are no plans for additional visits at this time.
If interested to learn more about this study, please complete the form here for someone to contact you. "here" would take you to the said form.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Long COVID | – | –Participants with Long COVID |
| Acute COVID | – | –Participants with acute COVID who tested positive for COVID without persistent symptoms |
| Postural Orthostatic Tachycardia Syndrome (POTS) | – | –Participants with postural orthostatic tachycardia syndrome (POTS) |
| Diabetic neuropathy | – | –Participants with diabetic neuropathy |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Male and females ages 18-80 who have been diagnosed with one of the following: 1. Long COVID defined by NIH PASC criteria OR 2. Acute COVID who tested positive for COVID without persistent symptoms OR 3. Postural orthostatic tachycardia syndrome (POTS) OR 4. Diabetic neuropathy
Key inclusion criteria (4 listed)
- Long COVID-19 defined by NIH PASC criteria OR
- Acute COVID-19 who tested positive for COVID-19 without persistent symptoms OR
- Postural orthostatic tachycardia syndrome (POTS) OR
- Diabetic neuropathy
Key exclusion criteria (5 listed)
- Clinical evidence of severe peripheral vascular disease
- History of ulceration, poor wound healing or vascular claudication
- History of allergic reaction to local anesthesia (for biopsy collection)
- Use of oral anticoagulants (aspirin or Plavix alone is allowed)
- History of a bleeding disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pathology and nervous system changes that occur in patients suffering from sensory and autonomic function changes
Time frame: Current - December 31,2025
This is a single site study of subjects with Long COVID, subject with a previous positive COVID test without persistent symptoms, and POTS subjects and diabetics. Neurocutaneous biosignatures will provide insight into the pathology and nervous system changes that occur in patients suffering from sensory and autonomic function changes.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
Related trials for Long COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Long COVID-19 and Acute COVID-19, run by CND Life Sciences at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathology and nervous system changes that occur in patients suffering from sensory and autonomic function changes (time frame: Current - December 31,2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.